Biophytis strengthens its financial position and extends its cash runway into Q1 2027

• Cash position strengthened to €3.0 million
• Most 2026 share warrants exercised
• Phase 2 study in obesity to start in Q1 2027
• Hong-Kong JV to start operations for preparing Phase 3 study in sarcopenia

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

Over the past few months, the Company has continued to implement its financial restructuring strategy, combining the mobilization of new resources primarily from the exercise of the 2026 warrants (BSA 2026) and the reduction of its financial debt through debt-to-equity conversion. These actions now make it possible to improve Biophytis’s financial visibility and extend its cash runway into the first quarter of 2027.